카포시육종 시장 예측(-2030년) : 유형별, 진단 방법별, 치료 방법별, 최종사용자별, 지역별 세계 분석

According to Stratistics MRC, the Global Kaposi Sarcoma Market is accounted for $108.69 million in 2023 and is expected to reach $150.92 million by 2030 growing at a CAGR of 4.8% during the forecast period. Kaposi Sarcoma (KS) is a rare cancer characterized by abnormal growth of blood vessels and lesions on the skin, mucous membranes, and internal organs. It is caused by infection with human herpesvirus 8 (HHV-8), often affecting individuals with compromised immune systems, such as those with HIV/AIDS or undergoing immunosuppressive therapy. Early diagnosis and effective management are crucial for improving outcomes in patients with Kaposi Sarcoma.

According to the study published in Clinical Cancer Research in March 2022, the study concluded that Pomalidomide is a safe and effective chemotherapy-sparing medication for the treatment of Kaposi sarcoma in people with or without HIV.

Market Dynamics:

Driver:

Growing prevalence of HIV/AIDS

HIV/AIDS weakens the immune system, making individuals more susceptible to developing kaposi sarcoma, a cancer associated with human herpesvirus 8 (HHV-8) infections. As HIV/AIDS prevalence raises globally, particularly in regions with limited access to antiretroviral therapy, the incidence of Kaposi sarcoma increases accordingly. This heightened prevalence drives demand for early detection, diagnosis, and treatment of Kaposi sarcoma, fueling market growth for therapeutic interventions, diagnostic tools, and supportive care services aimed at managing the disease in HIV/AIDS-affected populations.

Restraint:

Side effects of therapy

The therapies for kaposi sarcoma, including chemotherapy, radiation therapy, and immunotherapy, can lead to significant side effects. They may cause nausea, vomiting, hair loss, and bone marrow suppression, compromising patients' quality of life and treatment adherence. These side effects not only impact patient well-being but also deter treatment compliance and may necessitate dose adjustments or discontinuation, thereby limiting the market growth by reducing patient acceptance and adoption of kaposi sarcoma therapies.

Opportunity:

Advancements in diagnosis

Advancements in diagnosis significantly enhance early detection and treatment initiation. Improved diagnostic techniques such as immunohistochemistry and molecular testing enable more accurate and timely identification of kaposi sarcoma lesions, leading to earlier interventions and better patient outcomes. Additionally, advances in biomarker research facilitate risk stratification and personalized therapy approaches. These diagnostic innovations expand the market by increasing the demand for diagnostic tools, imaging equipment, and ancillary services related to kaposi sarcoma diagnosis and monitoring.

Threat:

High cost of treatment

Kaposi Sarcoma's high cost of treatment is primarily attributed to the complex and often prolonged therapeutic regimens involved. These regimens may include chemotherapy, radiation therapy, and targeted or immunotherapy, which are costly to administer and often require specialized medical expertise. Additionally, supportive care to manage treatment-related side effects further adds to the overall treatment expenses. The high cost of treatment can limit access to care, particularly in regions with limited healthcare resources, thereby hampering market growth.

Covid-19 Impact

The covid-19 pandemic has had a multifaceted impact on the kaposi sarcoma market. Healthcare systems strained by the pandemic diverted resources away from non-covid-related conditions, leading to delays in Kaposi sarcoma diagnosis and treatment. Economic uncertainties and healthcare resource reallocations also affected research funding and drug development efforts. Consequently, the pandemic exacerbated existing challenges in kaposi sarcoma management and impeded market growth by disrupting patient care pathways and research endeavours.

The epidemic kaposi sarcoma segment is expected to be the largest during the forecast period

The epidemic kaposi sarcoma segment is estimated to have a lucrative growth. Epidemic Kaposi Sarcoma refers to a form of KS that emerged during the HIV/AIDS epidemic, predominantly affecting immunocompromised individuals. It is caused by human herpes virus 8 (HHV-8) infections and is characterized by the development of multiple, often widespread, lesions on the skin, mucous membranes, and internal organs. The HIV/AIDS epidemic, particularly in regions with high prevalence, significantly contributed to the rise of epidemic KS cases.

The chemotherapy segment is expected to have the highest CAGR during the forecast period

The chemotherapy segment is anticipated to witness the highest CAGR growth during the forecast period. Chemotherapy is a cornerstone treatment for Kaposi Sarcoma, particularly in advanced or aggressive cases. The most commonly used chemotherapy agents include liposomal anthracyclines, paclitaxel, and vinca alkaloids. Chemotherapy aims to shrink or stabilize KS tumors, alleviate symptoms, and improve quality of life. Chemotherapy regimens have been shown to extend survival in KS patients which is accelerating the segment growth.

Region with largest share:

Asia Pacific is projected to hold the largest market share during the forecast period. Countries like India and Thailand have established strong healthcare infrastructure and research capabilities. Collaboration between governments, healthcare organizations and pharmaceutical companies in the region are improving patient outcomes. Further, increasing efforts to expand access to antiretroviral therapy, and raise awareness about HIV/AIDS and related cancers offer growth opportunities for the Kaposi Sarcoma market in Asia Pacific.

Region with highest CAGR:

North America is projected to have the highest CAGR over the forecast period, owing to the high prevalence of HIV/AIDS, advanced healthcare infrastructure, and increasing awareness about the disease. The region's well-established pharmaceutical and biotechnology industries contribute to the availability of advanced treatment options and clinical trials for Kaposi Sarcoma. Additionally, supportive government policies, robust research funding, and initiatives promoting HIV/AIDS awareness and prevention further bolster market growth.

Key players in the market

Some of the key players profiled in the Kaposi Sarcoma Market include Abbott Laboratories, AbbVie Inc, Biogen Inc, Bio-Rad Laboratories, Cornell Engineering, Celgene Corporation, Cipla Limited, Eli Lilly and Company, Genentech Inc, Johnson & Johnson, Leo Pharma A/S, Merck & Co. Inc, Novartis International AG, Pfizer Inc, Roche Holding AG, Siemens Healthineers, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical, Thermo Fisher Scientific Inc and Vertex Pharmaceuticals Incorporated.

Key Developments:

In August 2022, Researchers at Cornell Engineering and Weill Cornell Medicine designed a portable diagnostic device that has been deployed in clinical tests in Uganda to identify cases of Kaposi sarcoma. This common yet difficult-to-detect cancer often signals the presence of HIV infection.

Types Covered:

• Classic Kaposi Sarcoma
• Endemic Kaposi Sarcoma
• Epidemic Kaposi Sarcoma
• Immunosuppression-Associated Kaposi Sarcoma
• Latrogenic Kaposi Sarcoma
• Disseminated Kaposi Sarcoma
• Other Types

Diagnostic Methods Covered:

• Histopathology
• Immunohistochemistry (IHC)
• Polymerase Chain Reaction (PCR)
• Biopsy
• Other Diagnostic Methods

Treatment Modalities Covered:

• Antiretroviral Therapy (ART)
• Chemotherapy
• Immunotherapy
• Radiation Therapy
• Targeted Therapy
• Other Therapies

End Users Covered:

• Hospitals & Clinics
• Cancer Research Institutions
• Ambulatory Surgical Centers
• Home Healthcare
• Other End Users

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 End User Analysis
• 3.7 Emerging Markets
• 3.8 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Kaposi Sarcoma Market, By Type

• 5.1 Introduction
• 5.2 Classic Kaposi Sarcoma
• 5.3 Endemic Kaposi Sarcoma
• 5.4 Epidemic Kaposi Sarcoma
• 5.5 Immunosuppression-Associated Kaposi Sarcoma
• 5.6 Latrogenic Kaposi Sarcoma
• 5.7 Disseminated Kaposi Sarcoma
• 5.8 Other Types

6 Global Kaposi Sarcoma Market, By Diagnostic Method

• 6.1 Introduction
• 6.2 Histopathology
• 6.3 Immunohistochemistry (IHC)
• 6.4 Polymerase Chain Reaction (PCR)
• 6.5 Biopsy
• 6.6 Other Diagnostic Methods

7 Global Kaposi Sarcoma Market, By Treatment Modality

• 7.1 Introduction
• 7.2 Antiretroviral Therapy (ART)
• 7.3 Chemotherapy
• 7.4 Immunotherapy
• 7.5 Radiation Therapy
• 7.6 Targeted Therapy
• 7.7 Other Therapies

8 Global Kaposi Sarcoma Market, By End User

• 8.1 Introduction
• 8.2 Hospitals & Clinics
• 8.3 Cancer Research Institutions
• 8.4 Ambulatory Surgical Centers
• 8.5 Home Healthcare
• 8.6 Other End Users

9 Global Kaposi Sarcoma Market, By Geography

• 9.1 Introduction
• 9.2 North America
  • 9.2.1 US
  • 9.2.2 Canada
  • 9.2.3 Mexico
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 Italy
  • 9.3.4 France
  • 9.3.5 Spain
  • 9.3.6 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 Japan
  • 9.4.2 China
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 New Zealand
  • 9.4.6 South Korea
  • 9.4.7 Rest of Asia Pacific
• 9.5 South America
  • 9.5.1 Argentina
  • 9.5.2 Brazil
  • 9.5.3 Chile
  • 9.5.4 Rest of South America
• 9.6 Middle East & Africa
  • 9.6.1 Saudi Arabia
  • 9.6.2 UAE
  • 9.6.3 Qatar
  • 9.6.4 South Africa
  • 9.6.5 Rest of Middle East & Africa

10 Key Developments

• 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 10.2 Acquisitions & Mergers
• 10.3 New Product Launch
• 10.4 Expansions
• 10.5 Other Key Strategies

11 Company Profiling

• 11.1 Abbott Laboratories
• 11.2 AbbVie Inc
• 11.3 Biogen Inc
• 11.4 Bio-Rad Laboratories
• 11.5 Cornell Engineering
• 11.6 Celgene Corporation
• 11.7 Cipla Limited
• 11.8 Eli Lilly and Company
• 11.9 Genentech Inc
• 11.10 Johnson & Johnson
• 11.11 Leo Pharma A/S
• 11.12 Merck & Co. Inc
• 11.13 Novartis International AG
• 11.14 Pfizer Inc
• 11.15 Roche Holding AG
• 11.16 Siemens Healthineers
• 11.17 Takeda Pharmaceutical Company Limited
• 11.18 Teva Pharmaceutical
• 11.19 Thermo Fisher Scientific Inc
• 11.20 Vertex Pharmaceuticals Incorporated